Skip to content
PeptideAgent

IGF-1 LR3 regulatory status

Current status of IGF-1 LR3 in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

What is the current status of IGF-1 LR3?

Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 23, 2026
FDA and compounding
Never submitted to or reviewed by FDA for human use. IGF-1 LR3 is not a component of an approved drug (mecasermin is native IGF-1, a different molecule), has no USP monograph, and has not been placed on the 503A bulks list, so it cannot lawfully be compounded by 503A pharmacies or 503B outsourcing facilities. It is sold as a cell culture reagent and research chemical, which is not lawful for human use.
WADA
WADA prohibited
Access path
  1. No lawful United States access path identified on the last verified date.
  2. Not available as an FDA approved product, not nominated for the 503A bulks list, and not eligible for compounding under section 503A or 503B.
  3. Products labeled research use only are not lawful for human use and are not verified for identity or purity.

Full IGF-1 LR3 page: evidence, dosing in the literature, and sources

How has the status of IGF-1 LR3 changed over time?

  1. WADA

    WADA publishes the 2027 Prohibited List

    WADA published the 2027 Prohibited List on September 21, 2026, and it takes effect January 1, 2027. The S2 peptide hormone and growth factor classes are unchanged. BPC-157 is still named under S0, and MOTS-c is still named under S4.4 as an activator of AMP-activated protein kinase. WADA added a note that many peptides without approval for human use fall under S0 or another section, and that a peptide not named on the list may still be prohibited. GLP-1 receptor agonists such as semaglutide and tirzepatide are still not on the list.

    Source: WADA 2027 Prohibited List
  2. WADA

    WADA 2026 Prohibited List takes effect

    The 2026 WADA Prohibited List took effect on January 1, 2026 and continues to prohibit the S2 peptide hormone and growth factor classes (GHRH analogs, growth hormone secretagogues, GH fragments, IGF-1 and analogs, MGF, thymosin beta-4 and derivatives, hCG and GnRH-class releasing factors in males), myostatin inhibitors, insulin and the AMPK activator MOTS-c under S4, desmopressin under S5, and BPC-157 under S0. GLP-1 receptor agonists such as semaglutide and tirzepatide are not on the list.

    Source: WADA Prohibited List
  3. WADA

    WADA 2025 Prohibited List keeps peptide hormones and growth factors banned at all times

    The 2025 WADA Prohibited List took effect on January 1, 2025. Section S2 (peptide hormones, growth factors, related substances and mimetics) covers GHRH analogs such as CJC-1295, sermorelin, and tesamorelin, growth hormone secretagogues such as ipamorelin, GHRP-2, GHRP-6, hexarelin, and ibutamoren (MK-677), growth hormone fragments such as AOD-9604, growth factors including IGF-1 and its analogs, MGF, and thymosin beta-4 (TB-500), and chorionic gonadotropin and releasing factors such as gonadorelin and kisspeptin (prohibited in males). Myostatin inhibitors such as ACE-031 fall under S4, insulin under S4 metabolic modulators, desmopressin under S5, and BPC-157 remains an S0 non-approved substance.

    Source: WADA Prohibited List

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for IGF-1 LR3 and the source of each dated event.

  1. [1]FDA prescribing information for Increlex (mecasermin) injection, via DailyMedFDA, 2024
  2. [2]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  3. [3]WADA Prohibited List, section S2 (names IGF-1 and its analogues)WADA, 2026
  4. [4]WADA 2027 Prohibited ListWADA, 2026